Final FDA Guidance on Trial Monitoring to Give More Detail on Creating Plans

Washington Drug Letter
An upcoming final FDA guidance on risk-based monitoring of clinical investigations will include more specifics for drugmakers on developing monitoring plans, as the industry has requested.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00